abma

ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protecting cells against various pathogens including viruses, intracellular bacteria, and parasites. ABMA selectively acts on host cell late endosomes rather than targeting the toxin or pathogen itself.

Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.

Anatumomab mafenatox (ABR-214936), a 73 KDa recombinant protein, targets the tumor-associated antigen 5T4 commonly expressed in malignancies. It is a conjugate comprising a modified form of SEA linked to a murine Fab. The primary adverse effects of Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness [1].

Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].

Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects.